Global systemic sclerosis treatment market size to grow

New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) — According to a research report published by Spherical Insights & Consulting, the Global systemic sclerosis treatment market size grow from USD 1,520.1 million in 2021 to USD 2,259.0 million by 2030, at a CAGR of 4.5% during the forecast period. Systemic sclerosis is an autoimmune disease that causes the skin and internal organs to harden and thicken. The exponential growth in the number of government initiatives and services available to promote knowledge about the disease and treatment options is a key driver of the development of, and demand for, systemic scleroderma treatments. Asia-Pacific is expected to experience the fastest growth over the forecast period.

Get a sample PDF brochure:

The Endothelin Receptor Antagonists segment will account for the largest market size during the forecast period

Based on Drug Type, Systemic Sclerosis Treatment Market is categorized into Immunosuppressants, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogs and others. In 2021, the endothelin receptor antagonists segment dominated the market with the largest market share of 20% and revenue of 304.02 million. Drugs belonging to the class known as endothelin receptor antagonists (ERA) are effective in blocking endothelin receptors, particularly type A receptors. This induces vasodilation, which can reduce the blood pressure and improve blood flow to organs such as the kidneys, liver and brain. Among these alternatives are ambrisentan, bosentan, sitaxsentan and macitentant. Pulmonary arterial hypertension (PAH) and scleroderma are treated with these drugs. Due to its effects on scleroderma, it is overused, resulting in market growth.

Hospital Pharmacy Segment will maintain a higher CAGR during the forecast period

Based on distribution channel, the systemic scleroderma treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. In 2021, hospital pharmacies dominated the market with the largest market share of 37% and a turnover of 562.4 million. Systemic sclerosis therapy is increasingly being used in hospitals and pharmacies to treat patients with uncontrolled autoimmune disorders such as systemic sclerosis, lupus erythematosus, and rheumatoid arthritis. This contributes to the rapid expansion of the hospital segment. Immunosuppressants and phosphodiesterase-V (PDE) inhibitors, both part of the systemic treatment of scleroderma, are used to help reduce the thickening effect of the disease on the skin.

Browse key industry information spread across 215pages with 163 market data tables and The figures & graphics of the report”Global systemic sclerosis treatment market sizeshare and COVID-19 impact analysis by drug class (immunosuppressants, calcium channel blockers, proton pump inhibitors, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, prostacyclin analogs and others), by type of disease (limited systemic sclerosis, diffuse systemic sclerosis, and systemic sclerosis Sine Scleroderma), by route of administration (oral and parenteral), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) and by region ( North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecasts 2021 – 2030.” in detail with the table of contents

Buy Now Full Report:

North America is expected to be the biggest market.

The systemic sclerosis treatment market has been segmented into five major regions: North America, Europe, APAC, Latin America and MEA. The systemic sclerosis treatment market in the North America region has grown due to the increase in R&D activities of several small and medium-sized companies to develop medical facilities in the healthcare sector. Additionally, the United States has kept its R&D tax credit low, which increases the demand for systemic sclerosis treatment in the market. Furthermore, the population of elderly people in the region is increasing at an alarming rate; however, America and Canada have the most prosperous aging populations due to government social security payments. For example, Nordson Corporation released a polyurethane tubing named 80 Durometer medical tubing to be used for medical applications. Asia-Pacific to maintain a higher CAGR during the forecast period.

Asia-Pacific market is expected to grow at the fastest CAGR between 2021 and 2030, driven by growing demand for several applications such as catheters and cannulas, drug delivery systems, blood therapy equipment systemic sclerosis and other special applications (smoke evacuation tubes and peristaltic pump tubing devices).

Find out before you buy this research report:

Key companies and recent developments: The report also provides elaborate analysis focusing on current business news and developments, including product development, innovations, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and others. This helps to assess the overall competition in the market. The major global vendors of Systemic Scleroderma Treatment market include Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Allergan, Actelion Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Biogen, Novartis AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Celgene Corporation, Ono Pharmaceutical Co. Ltd, Aspen Holdings, Corbus Pharmaceuticals, Pfizer Inc., Eli Lilly and Company, Bayer AG, Argentis Pharmaceuticals, LLC., Amgen Inc., Sanofi. And other key players.

For more information about your target market, please contact us below:

Call: +1 303 800 4326 (USA)

Call: +91 90289 24100 (APAC)

E-mail: [email protected], [email protected]

Contact us: us

Follow us: LinkedIn | Facebook | Twitter

About Terry Gongora

Check Also

Truepill closes funding round to refocus on Core

SAN MATEO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) — realpillthe company that is transforming consumer …